🍄 Doug Drysdale is the CEO of Cybin, a psychedelic research company developing novel delivery systems for psilocybin, next-gen psychedelic  tryptamine molecules and performing studies on human brains under the influence of psychedelics using powerful brain imaging technology.  In this episode of the Integration Conversation, Brom and Doug cover all aspects of Cybin's business, and answer questions like:    Why is Cybin's sublingual psilocybin potentially superior to offerings from Compass Pathways and Usona?   How might deuterated tryptamines provide a superior psychedelic experience compared to classic psychedelics like psilocybin and LSD?  Why is Cybin's partnership with brain imaging company Kernel so powerful?   and the ultimate question for investors:  is Cybin undervalued?   👇👇👇 Links 👇👇👇  📺 Watch on YouTube:  https://youtu.be/cAsFHlVLpeA💻 The Integration Co Website:  https:/theintegration.co  📝 My notes on psychedelic investing:  https://brompersonal.s3-us-west-2.amazonaws.com/assets/broms-notes-psychedelic-investing.pdf   🎧 Listen on Spotify and other podcast platforms:  https://anchor.fm/theintegrationco  🐦 brom on twitter:  https://twitter.com/therealbrom  🎇 Clips and other stuff on Instagram:  https://instagram.com/theintegrationco  💌 Email:   [email protected]  ⏰ Timestamps:  Disclaimer: This video is not financial advice. Brom holds shares in  Cybin,  Field Trip Health, Mind Med, Cybin and Compass Pathways.